About this trial
Post-stroke depression (PSD) is a common neuropsychiatric complication following stroke and has emerged as a major public health concern due to its adverse impact on post-stroke prognosis. Clinical studies have confirmed that early intervention with electroacupuncture can significantly reduce PSD incidence and alleviate depressive severity. Mechanistically, electroacupuncture exerts antidepressant effects through inhibition of the endoplasmic reticulum stress pathway and attenuation of neuronal apoptosis. Dexmedetomidine, a highly selective α₂-adrenergic receptor agonist, not only provides sedation and analgesia but also confers neuroprotective actions, including anti-inflammatory, anti-apoptotic, and blood-brain barrier protective effects. Its efficacy in preventing postpartum depression has been clinically validated. Given the substantial burden of PSD and the limitations of existing preventive approaches, the present study aims to investigate the value of a combined electroacupuncture and dexmedetomidine strategy for PSD prevention, with the goal of developing a safe and effective integrative treatment regimen for this frequent post-stroke complication.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Ischemic stroke with a disease course of less than 2 weeks;
Patients with high-risk PSD;
The patient can accept the treatment plan described in this trial and sign the informed consent form.
Disqualifiers
Cognitive impairment;
Severe aphasia or significant language impairment;
Disturbance of consciousness;
History of psychiatric disorders, including but not limited to depression, schizophrenia, and bipolar disorder;
Trial design
Parallel
Treatments tested in this trial
Dexmedetomidine
DrugIntranasal titration of dexmedetomidine (1μg/kg)
Electropuncture
DrugElectroacupuncture treatment
Normal Saline (NS)
Drug0.9% normal saline
Shame electropuncture
DrugShame electropuncture treatment
Treatment groups
Trial outcomes
Primary outcomes
The incidence of PSD 3 months after stroke
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Min Su
Lead sponsor
First Affiliated Hospital of Chongqing Medical University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options: